
National Association of Testing Authorities, Australia
Scope of Accreditation
Genomic Diagnostics
Site
GD QLD – Healius Pathology Pty Ltd
Accreditation No.
19619
Site No.
25049
Date of Accreditation
01 Jun 2017
Contact
Dr Nicole Chia
P: +61 (07) 31214660
Availability
Services available to external clients
Supervision
B (Branch)
Scope of Accreditation
GD QLD – Healius Pathology Pty Ltd
ISO 15189 (2012)
Human Pathology
Service | Product | Determinant |
---|---|---|
Cytogenetics - Detection of defined, unbalanced chromosomal abnormalities by in-situ hybridisation techniques | Amniotic fluid; Blood; Bone marrow; Chorionic villus tissue; Other body fluids; Other tissues - Malignant; Other tissues - Non-malignant; Paraffin embedded tissue; Smears; Tissues | Chromosomal rearrangement; Cytogenetic analysis and reporting; Pathogenic copy number changes |
Cytogenetics - Karyotype detection of balanced and/or unbalanced chromosome abnormalities | Amniotic fluid; Blood; Bone marrow; Chorionic villus tissue; Other tissues - Malignant; Other tissues - Non-malignant | Cytogenetic analysis and reporting; Pathogenic copy number changes |
Cytogenetics - Karyotype detection of unbalanced abnormalities | Amniotic fluid; Blood; Bone marrow; Chorionic villus tissue; Other tissues - Malignant; Other tissues - Non-malignant | Constitutional genetic abnormalities; Pathogenic copy number changes |
Immunopathology - Single HLA antigen typing | Blood | HLA-B27 |
Molecular genetics - Assay for defined mutation or polymorphism (including pharmacogenetic testing) - Targeted genes | Blood | α-Thalassaemia |
Y chromosome microdeletion | ||
β-Thalassaemia | ||
Apolipoprotein E genotyping; Factor V Leiden; Haemochromatosis; Methylenetetrahydrofolate reductase (MTHFR); Prothrombin variant | ||
Fragile X | ||
Molecular genetics - Genetic testing for chimerism and mosaic gene variants (cancer and somatic mosaicism) - Targeted genes | Blood; Bone marrow | Quantitative calculation of p210 positive BCR::ABL1 transcripts |
JAK2 mutation analysis | ||
Nucleophosmin 1 (NPM1) mutation | ||
FLT3-ITD (internal tandem duplication) mutation; FLT3-TKD (tyrosine kinase domain) mutation | ||
B and T-cell gene rearrangement studies | ||
Qualitative calculation of p190 positive BCR::ABL1 transcripts | ||
Molecular genetics - Genetic testing for chimerism and mosaic gene variants (cancer and somatic mosaicism) - Targeted panels for non-inherited (somatic) DNA/RNA changes | Formalin-fixed paraffin-embedded (FFPE) tissues; Fresh tissue; Tissues | Solid tumours |
The only data displayed is that deemed relevant and necessary for the clear description of the activities and services covered by the scope of accreditation.
Grey text appearing in a SoA is additional freetext providing further refinement or information on the data in the preceding line entry.
Accreditation No.
19619
Site No.
25049
Print date
01 Jul 2022
END OF SCOPE